Toxicity, Adverse Events, and Quality of Life Associated with the Treatment of Metastatic Castration-Resistant Prostate Cancer | Zendy

Şenol Tonyalı | Zendy; Hakan Bahadır Haberal | Zendy; Emrullah Söğütdelen | Zendy

Open Access

Toxicity, Adverse Events, and Quality of Life Associated with the Treatment of Metastatic Castration-Resistant Prostate Cancer

Author(s) -

Şenol Tonyalı,

Hakan Bahadır Haberal,

Emrullah Söğütdelen

Publication year - 2017

Publication title -

current urology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.476

H-Index - 13

eISSN - 1661-7657

pISSN - 1661-7649

DOI - 10.1159/000447176

Subject(s) - enzalutamide , medicine , prostate cancer , abiraterone acetate , cabazitaxel , docetaxel , adverse effect , oncology , quality of life (healthcare) , cancer , disease , androgen deprivation therapy , androgen receptor , nursing

Among males, prostate cancer (PCa) is the most common cancer in Europe and the second most common cancer worldwide, especially in those aged > 70 years. With the advent of novel alternative treatments, survival in patients with advanced PCa has increased. PCa is now considered a chronic disease. Survival is an important endpoint in advanced PCa, as is quality of life (QoL). The effects of the disease and its treatment on patient health-related QoL must be taken into account when selecting the most appropriate treatment options. The present literature review aimed to provide an overview of metastatic castration-resistant prostate cancer treatment modalities, with an emphasis on side effect profiles and general health-related QoL.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research